Fluidigm has appointed Evan Jones to its board of directors and its compensation committee. Jones is the managing member of jVen Capital, a life sciences-investment company. Prior to forming jVen Capital, he was co-founder, chairman, and CEO of Digene Corporation, a publicly traded biotechnology company focused on women's health and molecular-diagnostic testing.
Paired Ends
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Browse our free articlesYou can still register for access to our free content.